Title: Clinical presentation, pathological features and natural course of metastatic uveal melanoma (MUM) as an orphan and commonly fatal disease
Authors: Cerbone, L
Van Ginderdeuren, Rita
van den Oord, Joost
Fieuws, Steffen
Spileers, Werner
Van Eenoo, Liza
Wozniak, Agnieszka
Sternberg, C. N
Schoffski, P #
Issue Date: Sep-2009
Publisher: Pergamon-elsevier science ltd
Host Document: Ejc supplements vol:7 issue:2 pages:585-585
Conference: Joint ECCO 15 – 34th ESMO Multidisciplinary Congress edition:15th location:Berlin date:20-27 September 2009

Linda Cerbone,1,5 Rita Van Ginderdeuren,2 Joost Van den Oord,3 Steffen Fieuws,4 Werner Spileers, 2 Liza Van Eenoo,1 Agnieszka Wozniak,1 Cora N. Sternberg,5 Patrick Schöffski 1

1University Hospitals and Catholic University Leuven, Department of General Medical Oncology and Laboratory of Experimental Oncology, Leuven, Belgium
2University Hospitals Leuven, Department of Ophthalmology, Leuven, Belgium
3University Hospitals Leuven, Department of Pathology, Leuven, Belgium
4Catholic University Leuven, Center for Biostatistics and Bioinformatics, Leuven, Belgium
5 Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy

Background: Uveal melanoma (UM) is a rare disease characterized by an unpredictable course and variable outcome ranging from cure by local treatment to the occurrence of untreatable metastasis. The current project is focused on the characteristics of the metastatic phenotype of the disease.
Methods: We performed data collection from 76 pts with MUM treated in Leuven between 1957-2008. Statistical analysis involved nonparametric technics, Kaplan Meyer and log rank test.
Results: The median age at diagnosis of UM was 58 yrs (range 30-94). Common initial treatments were surgery (71%), brachytherapy (20%) and external beam RT (7%). MUM was more common in women (f:m ratio 48:28) and independent from the side of the primary tumour (left vs. right eye). Synchronous metastasis was found in only 9% of cases, all others had metachronous disease after a median interval of 40 mo (range, 7-420). Statistical analysis failed to identify predisposing factors for MUM with the exception of a significant negative correlation between age at diagnosis of UM and time until metastatic disease (Spearman ρ=-0.4, p<0.001). Metastasis in >1 organ, usually liver plus another site, was seen in 47% of cases. The most frequent metastatic site was the liver (96%), followed by lung (23%), subcutaneous (13%), bone (11%) and brain (3%) lesions. The median OS from diagnosis of UM was 46 months (range, 2-182), and only 4,5 months in pts with MUM (range, 1-128). 65% of MUM pts qualified for further treatment, including systemic therapy (60%), radiotherapy (7%) and surgery (7%). Systemic therapy (45 pts) included mainly chemo- (50%), chemo- plus hormones (12%), immuno- (3%) or hormonal therapy alone (3%). The most common drugs given were DTIC (43%), cisplatin (27%), tamoxifen (10%) or phase I agents (8%). Patient benefit (PR+SD) was seen in 16/45 pts (36%), including 2 PR.
Conclusions: In this orphan disease with female predominance metastasis occurs late, is mainly found but certainly not confined to the liver, and is associated with high morbidity, as >1/3 of pts do not qualify for further therapy. Advances in MUM can only be achieved by networking of sites interested in this tumour type with systematic collection of data and tissue to improve our understanding of the molecular biology of the disease.
Description: no
ISSN: 1359-6349
Publication status: published
KU Leuven publication type: IMa
Appears in Collections:Translational Cell & Tissue Research
Research Group Ophthalmology
Laboratory of Experimental Oncology
LUCAS - Centre for Care Research and Consultancy
Leuven Biostatistics and Statistical Bioinformatics Centre (L-BioStat)
# (joint) last author

Files in This Item:

There are no files associated with this item.


All items in Lirias are protected by copyright, with all rights reserved.